{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:54:58Z","timestamp":1790013298745,"version":"4.0.1"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>\n                    Sarecycline is the first narrow-spectrum tetracycline-class antibiotic being developed for acne treatment. In addition to exhibiting activity against important skin\/soft tissue pathogens, sarecycline exhibits targeted antibacterial activity against clinical isolates of\n                    <jats:named-content content-type=\"genus-species\">Cutibacterium acnes<\/jats:named-content>\n                    .\n                  <\/jats:p>","DOI":"10.1128\/aac.01297-18","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T05:57:50Z","timestamp":1541051870000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":58,"title":["Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris"],"prefix":"10.1128","volume":"63","author":[{"given":"George","family":"Zhanel","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Critchley","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn-Yao","family":"Lin","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Alvandi","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304050-00002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200405020-00002"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06354.x"},{"key":"e_1_3_2_5_2","first-page":"1407","article-title":"Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications","volume":"9","author":"Kircik LH","year":"2010","unstructured":"Kircik LH. 2010. Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. J Drugs Dermatol 9:1407\u20131411.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12370"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60321-8"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1981.tb15317.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3182"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0307-y"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp18X694457"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2016.04.003"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30039-6"},{"key":"e_1_3_2_15_2","first-page":"208","article-title":"Efficacy of tetracyclines in the treatment of acne vulgaris: a review","volume":"158","author":"Simonart T","year":"2008","unstructured":"Simonart T, Dramaix M, De Maertelaer V. 2008. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol 158:208\u2013216.","journal-title":"Br J Dermatol"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.7.1.55"},{"key":"e_1_3_2_17_2","first-page":"341","article-title":"The effect of oral tetracycline HCl and doxycycline on the intestinal flora","volume":"12","author":"Hinton NA","year":"1970","unstructured":"Hinton NA. 1970. The effect of oral tetracycline HCl and doxycycline on the intestinal flora. Curr Ther Res Clin Exp 12:341\u2013352.","journal-title":"Curr Ther Res Clin Exp"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.303"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/11319280-000000000-00000"},{"key":"e_1_3_2_20_2","volume-title":"Once-daily oral sarecycline 1.5 mg\/kg\/day for moderate to severe acne vulgaris: pooled data from two phase 3 pivotal studies","author":"Kircik LH","year":"2018","unstructured":"Kircik LH, Bhatia ND, Lain E, Moore A, Schlessinger J, Stein-Gold L, Tyring SK, Schmitz C, Boodhoo TI, Berk DR, Kaoukhov A. 2018. Once-daily oral sarecycline 1.5 mg\/kg\/day for moderate to severe acne vulgaris: pooled data from two phase 3 pivotal studies. Abstr Am Acad Dermatol Annu Meet, San Diego, CA."},{"key":"e_1_3_2_21_2","first-page":"987","article-title":"Once-daily oral sarecycline 1.5 mg\/kg\/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials","volume":"17","author":"Moore A","year":"2018","unstructured":"Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S, Kempers SE, Kircik LH, Parish JL, Rendon MI, Rich P, Stein-Gold L, Tyring SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR. 2018. Once-daily oral sarecycline 1.5 mg\/kg\/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol 17:987\u2013996.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp214"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.femsle.2005.02.034"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.8.1611"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.2.239"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.49.1127"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1135(98)00234-X"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-081X(02)00324-3"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2015.990373"},{"key":"e_1_3_2_30_2","first-page":"19","article-title":"Oral doxycycline in the management of acne vulgaris: current perspectives on clinical use and recent findings with a new double-scored small tablet formulation","volume":"8","author":"Del Rosso JQ","year":"2015","unstructured":"Del Rosso JQ. 2015. Oral doxycycline in the management of acne vulgaris: current perspectives on clinical use and recent findings with a new double-scored small tablet formulation. J Clin Aesthet Dermatol 8:19\u201326.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.01543"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.040618-0"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0294-z"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2015.09.008"},{"key":"e_1_3_2_35_2","first-page":"1","article-title":"In vitro studies on colonization resistance of the human gut microbiota to Candida albicans and the effects of tetracycline and Lactobacillus plantarum LPK","volume":"4","author":"Payne S","year":"2003","unstructured":"Payne S, Gibson G, Wynne A, Hudspith B, Brostoff J, Tuohy K. 2003. In vitro studies on colonization resistance of the human gut microbiota to Candida albicans and the effects of tetracycline and Lactobacillus plantarum LPK. Curr Issues Intest Microbiol 4:1\u20138.","journal-title":"Curr Issues Intest Microbiol"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/493508"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.03.017"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2016.09.007"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01693-15"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt107"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.446"},{"key":"e_1_3_2_42_2","volume-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 8th ed, vol 32. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"8"},{"key":"e_1_3_2_43_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\/performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\/performance standards for antimicrobial susceptibility testing, 10th ed, vol 35. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01297-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01297-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:20:30Z","timestamp":1645460430000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01297-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1128\/AAC.01297-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.01297-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"2018-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01297-18"}}